Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1E,4Z,6E)-4-(4-hydroxy-3-methoxybenzylidene)-1-(3-hydroxy-4-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
-
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site
(1E,6E)-4-(3,4-dimethoxybenzylidene)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
-
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site
(1E,6E)-4-(3-fluorobenzylidene)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
-
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site
(1E,6E)-4-(4-fluorobenzylidene)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
-
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site
(2S)-2-amino-3-[([(2R)-3-[(4-bromobenzyl)sulfanyl]-1-[(carboxymethyl)amino]-1-oxopropan-2-yl]carbamoyl)amino]propanoic acid
-
-
(3Z)-3-(1,3-benzothiazol-2-yl)-4-(4-methoxyphenyl)but-3-enoic acid
-
inhibitor based on binding mode of myricetin, contributuion of the Zn2+-chelating group to inhibitory activity
(S)-4-bromobenzyl glutathione
-
potent Glx-I inhibitor
(S)-4-bromobenzylglutathione cyclopentyl diester
-
competitive inhibitor of GLOI
(Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate
-
decreases glyoxalase I expression and activity relative to untreated control cells, cells undergo apoptosis, apoptosis increases further on co-incubation with high glucose
1'-hydroxy-6'-phenyl-3,4'-bipyridin-2'(1'H)-one
-
-
1-hydroxy-4,6-diphenylpyridin-2(1H)-one
-
-
1-hydroxy-4-phenyl-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2(1H)-one
-
-
1-hydroxy-6-(1-pentyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-phenylpyridin-2(1H)-one
-
-
1-hydroxy-6-(1H-indol-5-yl)-4-phenylpyridin-2(1H)-one
-
-
1-hydroxy-6-phenyl-4-(thiophen-3-yl)pyridin-2(1H)-one
-
-
1-hydroxy-6-phenyl-4-[4-(trifluoromethyl)phenyl]pyridin-2(1H)-one
-
-
1-hydroxy-6-[1-(2-methoxyethyl)-1H-indol-5-yl]-4-phenylpyridin-2(1H)-one
-
-
1-hydroxy-6-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-4-phenylpyridin-2(1H)-one
-
-
1-hydroxy-6-[1-(3-methoxypropyl)-1H-indol-5-yl]-4-phenylpyridin-2(1H)-one
-
-
1-hydroxy-6-[1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-4-phenylpyridin-2(1H)-one
-
-
2-([(4-methoxyphenyl)carbonyl]amino)-1-benzothiophene-3-carboxylic acid
-
inhibitor based on binding mode of myricetin
2-([(4-methoxyphenyl)carbonyl]amino)benzoic acid
-
inhibitor based on binding mode of myricetin
3-[[5-(1-hydroxy-6-oxo-4-phenyl-1,6-dihydropyridin-2-yl)-1H-indol-1-yl]methyl]benzamide
-
-
3-[[5-(1-hydroxy-6-oxo-4-phenyl-1,6-dihydropyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl]methyl]benzamide
-
-
4,6-diphenyl-N-hydroxypyridone
-
a lead compound for non-peptidic inhibitor screening against glyoxalase I
4-(biphenyl-4-yl)-1-hydroxy-6-phenylpyridin-2(1H)-one
-
-
4-(but-1-yn-1-yl)-1-hydroxy-6-phenylpyridin-2(1H)-one
-
-
4-bromoacetoxy-1-(S-glutathionyl)-acetoxy butane
-
competitive inhibition of GLO1, the inhibitor is able to covalently bind to the free sulfhydryl group of Cys60 in the hydrophobic binding pocket adjacent to the enzyme active site and partially inactivate the enzyme, no complete inhibition, binding structure analysis, overview
4-butyl-1-hydroxy-6-phenylpyridin-2(1H)-one
-
-
4-[(4E)-5-(3,4-dimethoxyphenyl)-2-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]-3-oxopenta-1,4-dien-1-yl]benzene-1,2-dicarbaldehyde
-
three-ring curcumin derivative, in binding model two rings lay in the opening of the active site, the third is buried into hydrophobic pocket site
6-(1-butyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1-hydroxy-4-phenylpyridin-2(1H)-one
-
-
baicalein
79% inhibition of rhGLO I at 0.1 mM
Baicalin
30% inhibition of rhGLO I at 0.1 mM
buthionine sulfoximine
-
58% loss in Gly-I activity by 0.05 mM buthionine sulfoximine
Co2+
apo form reactivated
fenoprofen
-
combined study of kinetic analysis, molecular docking, and molecular dynamics. A remarkable correlation is observed between the experimental inhibitory affinity and predicted binding free energy parameter. DELTAGbind,pred of a glyoxalase I/inhibitor complex can be efficiently used to interpolate the experimental inhibitory affinity of a ligand of similar nature in the glyoxalase I enzyme system. Electrostatic contribution plays an important role in the inhibitory mechanisms
glycerol
-
64% loss in Gly-I activity by 2.5% (v/v) glycerol, Gly-I inactivation by glycerol is fully prevented or reversed by 0.5 mM N-acetylcysteine
HgCl2
-
67% loss in Gly-I activity by 0.03 mM HgCl2, Gly-I inactivation by HgCl2 is fully prevented or reversed by 0.5 mM N-acetylcysteine
hyperin
below 5% inhibition of rhGLO I at 0.1 mM
isolupalbigenin
treatment of HL-60 cells leads to significant accumulation of substrate methylglyoxal and the caspase 3 activity of the cell lysate increases. Compound shows anti-proliferative activity against HL-60 cells
Ketoprofen
-
combined study of kinetic analysis, molecular docking, and molecular dynamics. A remarkable correlation is observed between the experimental inhibitory affinity and predicted binding free energy parameter. DELTAGbind,pred of a glyoxalase I/inhibitor complex can be efficiently used to interpolate the experimental inhibitory affinity of a ligand of similar nature in the glyoxalase I enzyme system. Electrostatic contribution plays an important role in the inhibitory mechanisms
Mg2+
apo form reactivated
naringenin
50% inhibition of rhGLO I at 0.1 mM
NH2-gamma-Gla[-Glu(CON(OH)-4-bromophenyl)Gly-OH]-OH
-
-
NH2-gamma-Glu[-D-Glu(CON(OH)-4-bromophenyl)-Gly-OH]-OH
-
-
NH2-gamma-Glu[-Dab(N-(4-bromobenzoyl)-N'-hydroxyl)-Gly-OH]-OH
-
-
NH2-gamma-Glu[-Glu(CON(OH)-4-bromophenyl)-Gly-OH]-OH
-
-
Ni2+
apo form reactivated
oroxylin A
140% inhibition of rhGLO I at 0.1 mM
rutin
-
competitve inhibition, structually related to glutathione, Dixon plot analysis, significantly lower inhibition than that with curcumin, pH 7.0, 30°C, results in a decrease of D-lactate release
S-(4-nitrobenzyloxycarbonyl)glutathione
-
-
S-(N-hydroxy-N-bromophenylcarbamoyl)gluthatione
-
IC50 0.06 microM
S-(N-hydroxy-N-chlorophenylcarbamoyl)gluthatione
-
IC50 0.09 microM
S-(N-hydroxy-N-methylcarbamoyl)glutathione
-
S-(N-hydroxy-N-p-bromophenylcarbamoyl)glutathione
-
S-(N-hydroxy-N-p-iodophenylcarbamoyl) glutathione
tight binding competitive inhibitor of human GLOI
S-(N-hydroxy-N-p-iodophenylcarbamoyl)glutathione
-
S-(N-hydroxy-N-phenylcarbamoyl)gluthatione
-
IC50 2.5 microM
S-(N-p-iodophenyl-N-hydroxycarbamoyl)glutathione
-
-
S-(p-bromobenzyl)glutathione
-
-
S-2,4-dinitrophenylglutathione
-
S-2,4-dinitrophenylglutathionylspermidine
-
S-4-bromobenzylglutathione
S-4-bromobenzylglutathione cyclopentyl diester
-
detanonoate, NO donor, competitive inhibitor, concentration-dependent down-regulation of glyoxalase I, increases intracellular methylglyoxal and causes apoptosis, overexpression of glyoxalase I protects against S-4-bromobenzylglutathione cyclopentyl diester-induced apoptosis under high glucose conditions
S-4-bromobenzylglutathionylspermidine
linear competitive inhibitor
S-nitroso-N-acetyl-D,L-penicillamine
-
released NO inhibits glyoxalase I by reversible modification at a critical thiol residue, inactivation is reversed by reducing agents
S-nitrosocysteine
-
released NO inhibits glyoxalase I by reversible modification at a critical thiol residue, inactivation is reversed by reducing agents
S-nitrosoglutathione
-
glyoxal I activity in cells decreases rapidly within 30 min and reaches 10% of the control level within 2 h, activity returns to approx. 80% and 70% after removal of S-nitrosoglutathione or incubation with dithiothreitol, respectively, released NO inhibits glyoxalase I by reversible modification at a critical thiol residue, inactivation is reversed by reducing agents
S-p-bromobenzylglutathione
S-p-nitrobenzyloxycarbonylglutathione
-
Tolmetin
-
combined study of kinetic analysis, molecular docking, and molecular dynamics. A remarkable correlation is observed between the experimental inhibitory affinity and predicted binding free energy parameter. DELTAGbind,pred of a glyoxalase I/inhibitor complex can be efficiently used to interpolate the experimental inhibitory affinity of a ligand of similar nature in the glyoxalase I enzyme system. Electrostatic contribution plays an important role in the inhibitory mechanisms. Tolmetin coordinates with the zinc ion
zinc (2S)-2-amino-3-([(3R)-3-([[(4-bromophenyl)(hydroxy)carbamoyl]sulfanyl]methyl)-4-[(carboxylatomethyl)amino]-4-oxobutanoyl]amino)propanoate
-
-
zinc (2S)-2-amino-3-[([(2R)-3-[[(4-bromophenyl)(hydroxy)carbamoyl]sulfanyl]-1-[(carboxylatomethyl)amino]-1-oxopropan-2-yl]carbamoyl)amino]propanoate
-
-
Zn2+
apo form reactivated
Zomepirac
-
combined study of kinetic analysis, molecular docking, and molecular dynamics. A remarkable correlation is observed between the experimental inhibitory affinity and predicted binding free energy parameter. DELTAGbind,pred of a glyoxalase I/inhibitor complex can be efficiently used to interpolate the experimental inhibitory affinity of a ligand of similar nature in the glyoxalase I enzyme system. Electrostatic contribution plays an important role in the inhibitory mechanisms
bisdemethoxycurcumin
-
bisdemethoxycurcumin
-
combined study of kinetic analysis, molecular docking, and molecular dynamics. A remarkable correlation is observed between the experimental inhibitory affinity and predicted binding free energy parameter. DELTAGbind,pred of a glyoxalase I/inhibitor complex can be efficiently used to interpolate the experimental inhibitory affinity of a ligand of similar nature in the glyoxalase I enzyme system. Electrostatic contribution plays an important role in the inhibitory mechanisms. Bisdemethoxycurcumin coordinates with the zinc ion
curcumin
-
competitve inhibition, structually related to glutathione, Dixon plot analysis, pH 7.0, 30°C, more efficient inhibition of GLO1 compared to quercetin, myricetin, kaempferol, luteolin, or rutin as inhibitor, results in a decrease of D-lactate release
curcumin
efficient inhibitor
curcumin
-
combined study of kinetic analysis, molecular docking, and molecular dynamics. A remarkable correlation is observed between the experimental inhibitory affinity and predicted binding free energy parameter. DELTAGbind,pred of a glyoxalase I/inhibitor complex can be efficiently used to interpolate the experimental inhibitory affinity of a ligand of similar nature in the glyoxalase I enzyme system. Electrostatic contribution plays an important role in the inhibitory mechanisms. Curcumin coordinates with the zinc ion
GSH
-
non-linear inhibition
indomethacin
-
indomethacin
-
combined study of kinetic analysis, molecular docking, and molecular dynamics. A remarkable correlation is observed between the experimental inhibitory affinity and predicted binding free energy parameter. DELTAGbind,pred of a glyoxalase I/inhibitor complex can be efficiently used to interpolate the experimental inhibitory affinity of a ligand of similar nature in the glyoxalase I enzyme system. Electrostatic contribution plays an important role in the inhibitory mechanisms. Indomethacin coordinates with the zinc ion and is able to occupy all four enzyme subsites, both subsites C and D may be occupied simultaneously
kaempferol
60% inhibition of rhGLO I at 0.1 mM
kaempferol
-
competitve inhibition, structually related to glutathione, Dixon plot analysis, significantly lower inhibition than that with curcumin, pH 7.0, 30°C, results in a decrease of D-lactate release
luteolin
90% inhibition of rhGLO I at 0.1 mM
luteolin
-
competitve inhibition, structually related to glutathione, Dixon plot analysis, significantly lower inhibition than that with curcumin, pH 7.0, 30°C, results in a decrease of D-lactate release
myricetin
75% inhibition of rhGLO I at 0.1 mM
myricetin
-
competitve inhibition, structually related to glutathione, Dixon plot analysis, significantly lower inhibition than that with curcumin, pH 7.0, 30°C, results in a decrease of D-lactate release
myricetin
-
substrate transition-state (Zn2+-bound methylglyoxal-glutathione hemithioacetal) mimetic inhibitor
quercetin
-
-
quercetin
78% inhibition of rhGLO I at 0.1 mM
quercetin
-
competitve inhibition, structually related to glutathione, Dixon plot analysis, significantly lower inhibition than that with curcumin, pH 7.0, 30°C, results in a decrease of D-lactate release
S-4-bromobenzylglutathione
-
S-4-bromobenzylglutathione
-
-
S-p-bromobenzylglutathione
-
-
S-p-bromobenzylglutathione
-
competitive
S-p-bromobenzylglutathione
-
S-p-bromobenzylglutathione
55% inhibition of rhGLO I at 0.1 mM
additional information
-
-
-
additional information
-
substrate-analogue inhibitors and transition-state inhibitors
-
additional information
-
reducing glyoxalase I RNA levels with advancing stage of Alzheimers disease and with increasing age, continuously decrease in middle and late stages of Alzheimers disease, glyoxalase I activity neither significantly changes with age nor with the course of the disease
-
additional information
-
exposure of HPMC cells to heat-sterilized peritoneal dialysis fluids results in reduced GLO-I activity, GSH depletion, and a decrease in cell viability. Pretreatment of heat-sterilized peritoneal dialysis with either a combination of GLO-I and GSH markedly reduces inhibitory effects toward HPMC cells. Exposure of HPMC cells to L-2-oxothiazolidine-carboxylic acid increases cellular GSH and prevents loss of GLO-I activity in response to heat-sterilized peritoneal dialysis
-
additional information
-
posttranslational modification of Glo1 by oxidized glutathione (GSSG) and nitrosylation strongly inhibits Glo1 activity
-
additional information
-
design of 4-(7-azaindole)-substituted 6-phenyl-N-hydroxypyridones, thermodynamic binding parameters, binding modeling using the enzyme's crystal structure, overview. Inhibitory activity of 6-phenyl-N-hydroxypyridones with various substituents at 4-position
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenoma
Low red blood cell levels of deglycating enzymes in colorectal cancer patients.
Adrenal Hyperplasia, Congenital
Extended MHC haplotypes in 21-hydroxylase-deficiency congenital adrenal hyperplasia: shared genotypes in unrelated patients.
Adrenal Hyperplasia, Congenital
Heterozygotes and cryptic patients in families of patients with congenital adrenal hyperplasia (21-hydroxylase deficiency). HLA and glyoxalase I typing and hormonal studies.
Adrenal Hyperplasia, Congenital
Sharing of MHC haplotypes among apparently unrelated patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Alzheimer Disease
20S proteasome and glyoxalase 1 activities decrease in erythrocytes derived from Alzheimer's disease patients.
Alzheimer Disease
Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.
Alzheimer Disease
HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type.
Alzheimer Disease
Levels of Receptor for Advanced Glycation End Products and Glyoxalase-1 in the Total Circulating Extracellular Vesicles from Mild Cognitive Impairment and Different Stages of Alzheimer's Disease Patients.
Alzheimer Disease
Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease.
Alzheimer Disease
Role for glyoxalase I in Alzheimer's disease.
Anemia, Hemolytic
Major histocompatibility complex markers in patients with nomifensine-induced immune hemolytic anemia.
Asthma
Absolute Quantification of Allergen Glb33 in Rice by Liquid Chromatography-Mass Spectrometry using Two Isotope-Labeled Standard Peptides.
Atherosclerosis
A Glyoxalase-1 Knockdown Does Not Have Major Short Term Effects on Energy Expenditure and Atherosclerosis in Mice.
Atherosclerosis
Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes.
Atherosclerosis
Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice.
Atherosclerosis
Gender difference in glyoxalase 1 activity of atherosclerotic carotid artery lesions.
Atherosclerosis
Methylglyoxal and glyoxalase I in atherosclerosis.
Atherosclerosis
Reduced glyoxalase 1 activity in carotid artery plaques of nondiabetic patients with increased hemoglobin A1c level.
Brain Diseases
Enhancement of glyoxalase 1, a polyfunctional defense enzyme, by quercetin in the brain in streptozotocin-induced diabetic rats.
Breast Neoplasms
A possible regulatory role of 17beta-estradiol and tamoxifen on glyoxalase I and glyoxalase II genes expression in MCF7 and BT20 human breast cancer cells.
Breast Neoplasms
Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade.
Breast Neoplasms
Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2.
Breast Neoplasms
Expression of glyoxalase I and II in normal and breast cancer tissues.
Breast Neoplasms
Glyoxalase 1 and protein kinase C? as potential therapeutic targets for late-stage breast cancer.
Breast Neoplasms
Glyoxalase 1 expression analysis by immunohistochemistry in breast cancer.
Breast Neoplasms
Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive breast cancer stem cells.
Breast Neoplasms
Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor.
Breast Neoplasms
Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.
Breast Neoplasms
Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative.
Breast Neoplasms
Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.
Breast Neoplasms
Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.
Breast Neoplasms
Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Breast Neoplasms
Resveratrol, Curcumin and Piperine Alter Human Glyoxalase 1 in MCF-7 Breast Cancer Cells.
Breast Neoplasms
The influence of glyoxalase 1 gene polymorphism on its expression at different stages of breast cancer in Egyptian women.
Breast Neoplasms
Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes.
Breast Neoplasms
Up-regulation of the tumor promoter Glyoxalase-1 indicates poor prognosis in breast cancer.
Carcinogenesis
Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Carcinogenesis
Changes in concentrations of methylglyoxal, D-lactate and glyoxalase activities in liver and plasma of rats fed a 3'-methyl-4-dimethylaminoazobenzene-rich diet.
Carcinogenesis
Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Carcinogenesis
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Carcinogenesis
Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.
Carcinogenesis
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Carcinogenesis
Potential of glycative stress targeting for cancer prevention.
Carcinoma
Analysis of glyoxalase-I from normal and tumor tissue from human colon.
Carcinoma
Cloning and characterization of human colon glyoxalase-I.
Carcinoma
Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.
Carcinoma
Glyoxalase 1 as a candidate for indicating the metastatic potential of SN12C human renal cell carcinoma cell clones.
Carcinoma
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
Carcinoma
Glyoxalase 1, regulated by LncRNA MALAT1, promotes malignant development of esophageal squamous cell carcinoma.
Carcinoma
Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.
Carcinoma
Glyoxalase I phenotype as a potential risk factor for prostate carcinoma.
Carcinoma
Interaction of aldehydes with glyoxalase I and the status of several aldehyde metabolizing enzymes of Ehrlich ascites carcinoma cells.
Carcinoma
Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative.
Carcinoma
The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice.
Carcinoma, Hepatocellular
Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation
Carcinoma, Hepatocellular
Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation.
Carcinoma, Hepatocellular
Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).
Carcinoma, Lewis Lung
The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice.
Carcinoma, Renal Cell
Glyoxalase 1 as a candidate for indicating the metastatic potential of SN12C human renal cell carcinoma cell clones.
Carcinoma, Renal Cell
Overexpression of glyoxalase system enzymes in human kidney tumor.
Carcinoma, Squamous Cell
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
Carcinoma, Squamous Cell
Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.
Cardiovascular Diseases
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Cardiovascular Diseases
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Carotid Artery Diseases
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
Carotid Stenosis
Reduced glyoxalase 1 activity in carotid artery plaques of nondiabetic patients with increased hemoglobin A1c level.
Celiac Disease
Properdin factor B and glyoxalase 1 polymorphism in celiac disease.
Chronic Limb-Threatening Ischemia
Glyoxalase-1 Overexpression Reverses Defective Proangiogenic Function of Diabetic Adipose-Derived Stem Cells in Streptozotocin-Induced Diabetic Mice Model of Critical Limb Ischemia.
Colonic Neoplasms
Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway.
Colorectal Neoplasms
Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Corneal Dystrophies, Hereditary
Linkage analysis in granular corneal dystrophy (Groenouw I), Schnyder's crystalline corneal dystrophy, and Reis-Bücklers' corneal dystrophy.
Dermatitis, Atopic
Absolute Quantification of Allergen Glb33 in Rice by Liquid Chromatography-Mass Spectrometry using Two Isotope-Labeled Standard Peptides.
Diabetes Complications
C332C genotype of glyoxalase 1 and its association with late diabetic complications.
Diabetes Complications
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Diabetes Complications
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Diabetes Complications
Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway.
Diabetes Complications
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Diabetes Complications
Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications.
Diabetes Complications
Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase.
Diabetes Complications
Negative association between erythrocyte reduced glutathione concentration and diabetic complications.
Diabetes Complications
The Antidepressant-Like Effects of Hesperidin in Streptozotocin-Induced Diabetic Rats by Activating Nrf2/ARE/Glyoxalase 1 Pathway.
Diabetes Mellitus
Association of glyoxalase I allotypes with Graves' disease and diabetes mellitus.
Diabetes Mellitus
Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients.
Diabetes Mellitus
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Diabetes Mellitus
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Diabetes Mellitus
Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose.
Diabetes Mellitus
The combination of loss of glyoxalase1 and obesity results in hyperglycemia.
Diabetes Mellitus, Type 1
HLA-A, B, C, DR antigens, Bf, C4 and glyoxalase I (GLO) polymorphisms in French Basques with insulin-dependent diabetes mellitus (IDDM).
Diabetes Mellitus, Type 1
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Diabetes Mellitus, Type 2
Association of Two Glyoxalase 1 Gene Polymorphisms with Nephropathy and Retinopathy in Type 2 Diabetes.
Diabetes Mellitus, Type 2
C332C genotype of glyoxalase 1 and its association with late diabetic complications.
Diabetes Mellitus, Type 2
Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes.
Diabetes Mellitus, Type 2
Effect of metformin treatment in patients with type 2 diabetes with respect to glyoxalase 1 activity in atherosclerotic lesions.
Diabetes Mellitus, Type 2
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Diabetes Mellitus, Type 2
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
Diabetes Mellitus, Type 2
The combination of loss of glyoxalase1 and obesity results in hyperglycemia.
Diabetic Angiopathies
The characterisation and functional analysis of the human glyoxalase-1 gene using methods of bioinformatics.
Diabetic Cardiomyopathies
Adeno-Associated Viral Transfer of Glyoxalase-1 Blunts Carbonyl and Oxidative Stresses in Hearts of Type 1 Diabetic Rats.
Diabetic Nephropathies
Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality.
Diabetic Nephropathies
Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway.
Diabetic Nephropathies
Knockdown of Glo1 mimics diabetic nephropathy in non-diabetic mice.
Diabetic Nephropathies
The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy.
Diabetic Nephropathies
Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats.
Diabetic Neuropathies
Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients.
Diabetic Neuropathies
Expression of macrophage migration inhibitory factor in footpad skin lesions with diabetic neuropathy.
Diabetic Retinopathy
CANDESARTAN ATTENUATES DIABETIC RETINAL VASCULAR PATHOLOGY BY RESTORING GLYOXALASE-I FUNCTION.
Diabetic Retinopathy
Expression analysis of glyoxalase I gene among patients of diabetic retinopathy.
Diabetic Retinopathy
Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions.
Diabetic Retinopathy
TRPC proteins contribute to development of diabetic retinopathy and regulate glyoxalase 1 activity and methylglyoxal accumulation.
Dyslipidemias
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Endometrial Neoplasms
Comment on 'Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'
Endometrial Neoplasms
Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
Endometrial Neoplasms
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Endometrial Neoplasms
Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Endometrial Neoplasms
Response to 'Comment on Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'
Endometrial Neoplasms
[Expression of glyoxalase I and its effect on cell proliferation and apoptosis in endometrial carcinoma].
Epilepsy
LncRNA NEAT1 affects inflammatory response by targeting miR-129-5p and regulating Notch signaling pathway in epilepsy.
Epilepsy
Role of glyoxalase I gene polymorphisms in late-onset epilepsy and drug-resistant epilepsy.
Esophageal Squamous Cell Carcinoma
Glyoxalase 1, regulated by LncRNA MALAT1, promotes malignant development of esophageal squamous cell carcinoma.
Fatty Liver
Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Fatty Liver
Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Fibrosarcoma
cDNA cloning and characterization of human glyoxalase I isoforms from HT-1080 cells.
Fibrosarcoma
Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma.
Glioblastoma
Biomarker discovery: a proteomic approach for brain cancer profiling.
Glioma
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents.
Graves Disease
Association of glyoxalase I allotypes with Graves' disease and diabetes mellitus.
Hemangioma, Cavernous, Central Nervous System
GLYOXALASE I A111E, PARAOXONASE 1 Q192R AND L55M POLYMORPHISMS IN ITALIAN PATIENTS WITH SPORADIC CEREBRAL CAVERNOUS MALFORMATIONS: A PILOT STUDY.
Hemangioma, Cavernous, Central Nervous System
Spectrophotometric Method for Determining Glyoxalase 1 Activity in Cerebral Cavernous Malformation (CCM) Disease.
Hyperglycemia
Compensatory mechanisms for methylglyoxal detoxification in experimental & clinical diabetes.
Hyperglycemia
Decreasing Intracellular Superoxide Corrects Defective Ischemia-induced New Vessel Formation in Diabetic Mice.
Hyperglycemia
Effect of antidiabetic compounds on glyoxalase I activity in experimental diabetic rat liver.
Hyperglycemia
Erythrocyte glyoxalase activity in genetically obese (ob/ob) and streptozotocin diabetic mice.
Hyperglycemia
Glycolytic overload-driven dysfunction of periodontal ligament fibroblasts in high glucose concentration, corrected by glyoxalase 1 inducer.
Hyperglycemia
Glyoxalase 1 Modulation in Obesity and Diabetes.
Hyperglycemia
Glyoxalase 1 Prevents Chronic Hyperglycemia Induced Heart-Explant Derived Cell Dysfunction.
Hyperglycemia
Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats.
Hyperglycemia
Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro.
Hyperglycemia
Upregulation of glyoxalase I fails to normalize methylglyoxal levels: a possible mechanism for biochemical changes in diabetic mouse lenses.
Hypersensitivity
Absolute Quantification of Allergen Glb33 in Rice by Liquid Chromatography-Mass Spectrometry using Two Isotope-Labeled Standard Peptides.
Hypersensitivity
Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes.
Hypersensitivity
Methylglyoxal evokes pain by stimulating TRPA1.
Hypersensitivity
Oryza sativa drought-, heat-, and salt-induced RING finger protein 1 (OsDHSRP1) negatively regulates abiotic stress-responsive gene expression.
Hypertension
Grape powder supplementation prevents oxidative stress-induced anxiety-like behavior, memory impairment, and high blood pressure in rats.
Hypertension
Reduction of glyoxalase 1 (GLO1) aggravates cerebrovascular remodeling via promoting the proliferation of basilar smooth muscle cells in hypertension.
Infections
Carbonyl stress phenomena during chronic infection with Opisthorchis felineus.
Infections
Defence against methylglyoxal in Group A Streptococcus: a role for Glyoxylase I in bacterial virulence and survival in neutrophils?
Infections
Glyoxalase in tumourigenesis and multidrug resistance.
Infections
Identification of a maize kernel stress-related protein and its effect on aflatoxin accumulation
Infections
Identification of a maize kernel stress-related protein and its effect on aflatoxin accumulation.
Infections
[The association between glyoxalase I and paracoccidioidomycosis infection]
Insulin Resistance
Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes.
Insulin Resistance
GLP-1 improves adipose tissue glyoxalase activity and capillarization improving insulin sensitivity in type 2 diabetes.
Insulin Resistance
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Insulin Resistance
Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.
Insulin Resistance
Preventive Effect of Eucalyptol on the Formation of Aorta Lesions in the Diabetic-Atherosclerotic Rat.
Insulin Resistance
Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation.
Intestinal Volvulus
A stress-responsive glyoxalase I from the parasitic nematode Onchocerca volvulus.
Kidney Diseases
RAGE and glyoxalase in kidney disease.
Kidney Neoplasms
Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer.
lactoylglutathione lyase deficiency
Dicarbonyl stress in clinical obesity.
lactoylglutathione lyase deficiency
Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient.
Leishmaniasis
Crystallization and preliminary X-ray analysis of Leishmania major glyoxalase I.
Leishmaniasis, Visceral
Glyoxalase I from Leishmania donovani: a potential target for anti-parasite drug.
Leukemia
Further studies on liver glyoxalase I and glyoxalase II. Activity in mice bearing sarcoma 180 and L1210 leukemia.
Leukemia
Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis.
Leukemia
Glyoxalase-I is a novel target against Bcr-Abl(+) leukemic cells acquiring stem-like characteristics in a hypoxic environment.
Leukemia
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Leukemia
Studies on methylglyoxal. II. Changes of methylglyoxal level accompanying the changes of glyoxalase I and II activities in mice bearing L1210 leukemia and sarcoma 180.
Leukemia
Troglitazone reverses the multiple drug resistance phenotype in cancer cells.
Leukemia, Lymphoid
Synthesis and evaluation of N-alkanoyl-S-benzyl-L-cysteinylglutamic acid esters as glyoxalase I inhibitors and anticancer agents.
Leukemia, Myeloid
Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells.
Liver Cirrhosis
Imbalance in the glutathione system in Opisthorchis felineus infected liver promotes hepatic fibrosis.
Liver Diseases
Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Liver Diseases
Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis.
Liver Diseases
Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Liver Diseases
The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).
Lung Neoplasms
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Lung Neoplasms
Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I.
Lung Neoplasms
TLSC702, a Novel Inhibitor of Human Glyoxalase I, Induces Apoptosis in Tumor Cells.
Lupus Erythematosus, Systemic
HLA-A,B,C, and DR antigens, GLO I and Bf marker profiles in 75 Cape coloured patients with systemic lupus erythematosus (SLE).
Lymphoma, Non-Hodgkin
The purification and characterization of liver glyoxalase I from normal mice and from mice bearing a lymphosarcoma.
Malaria
Glyoxalase-I activity levels in peripheral blood of Ghanaian Africans with or without Plasmodium falciparum.
Malaria
Mechanism of action of glycyrrhizin against Plasmodium falciparum.
Malaria
Tight-binding inhibitors efficiently inactivate both reaction centers of monomeric Plasmodium falciparum glyoxalase 1.
Melanoma
Genetic Target Modulation Employing CRISPR/Cas9 Identifies Glyoxalase 1 as a Novel Molecular Determinant of Invasion and Metastasis in A375 Human Malignant Melanoma Cells In Vitro and In Vivo.
Melanoma
GLO1 overexpression in human malignant melanoma.
Metabolic Syndrome
Thiamine reduced metabolic syndrome symptoms in rats via down-regulation of hepatic nuclear factor-k? and induction activity of glyoxalase-I.
Multiple Sclerosis
Advanced Glycation Endproducts Are Increased in the Animal Model of Multiple Sclerosis but Cannot Be Reduced by Pyridoxamine Treatment or Glyoxalase 1 Overexpression.
Muscular Dystrophies
Glyoxalase enzyme system in human muscular dystrophy.
Myeloproliferative Disorders
Platelet glyoxalases in thrombocytosis.
Neoplasm Metastasis
Genetic Target Modulation Employing CRISPR/Cas9 Identifies Glyoxalase 1 as a Novel Molecular Determinant of Invasion and Metastasis in A375 Human Malignant Melanoma Cells In Vitro and In Vivo.
Neoplasm Metastasis
Glyoxalase 1, regulated by LncRNA MALAT1, promotes malignant development of esophageal squamous cell carcinoma.
Neoplasm Metastasis
Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
Neoplasm Metastasis
[Metformin--new treatment strategies for gynecologic neoplasms].
Neoplasms
2D- and 3D-QSAR modelling, molecular docking and in vitro evaluation studies on 18?-glycyrrhetinic acid derivatives against triple-negative breast cancer cell line.
Neoplasms
A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides.
Neoplasms
Addition of hydrophobic side chains improve the apoptosis inducibility of the human glyoxalase I inhibitor, TLSC702.
Neoplasms
Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor.
Neoplasms
Analysis of glyoxalase-I from normal and tumor tissue from human colon.
Neoplasms
Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis.
Neoplasms
Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Neoplasms
Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade.
Neoplasms
Carcinostatic activity of methylglyoxal and related substances in tumour-bearing mice.
Neoplasms
Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.
Neoplasms
Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Neoplasms
Computational and experimental exploration of the structure-activity relationships of flavonoids as potent glyoxalase-I inhibitors.
Neoplasms
Copy number variation of glyoxalase I.
Neoplasms
Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I.
Neoplasms
Design, synthesis and biological evaluation of novel glyoxalase I inhibitors possessing diazenylbenzenesulfonamide moiety as potential anticancer agents.
Neoplasms
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Neoplasms
Differences among human tumor cell lines in the expression of glutathione transferases and other glutathione-linked enzymes.
Neoplasms
Differentiation and apoptosis induction by lovastatin and ?-tocotrienol in HL-60 cells via Ras/ERK/NF-?B and Ras/Akt/NF-?B signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase.
Neoplasms
Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.
Neoplasms
Effect of piceatannol-rich passion fruit seed extract on human glyoxalase I-mediated cancer cell growth.
Neoplasms
Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2.
Neoplasms
Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial.
Neoplasms
Ellagic acid: A potent glyoxalase-I inhibitor with a unique scaffold.
Neoplasms
Embryonic atrazine exposure elicits proteomic, behavioral, and brain abnormalities with developmental time specific gene expression signatures.
Neoplasms
Evaluation of potential flavonoid inhibitors of glyoxalase-I based on virtual screening and in vitro studies.
Neoplasms
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Neoplasms
Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.
Neoplasms
GLO1-A novel amplified gene in human cancer.
Neoplasms
Glutathione S-transferases in normal and malignant human colon tissue.
Neoplasms
Glycerophosphoglycerol, Beta-alanine, and pantothenic Acid as metabolic companions of glycolytic activity and cell migration in breast cancer cell lines.
Neoplasms
Glyoxalase 1 expression analysis by immunohistochemistry in breast cancer.
Neoplasms
Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer.
Neoplasms
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
Neoplasms
Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive breast cancer stem cells.
Neoplasms
Glyoxalase 1-419C>A Variant Is Associated with Oxidative Stress: Implications in Prostate Cancer Progression.
Neoplasms
Glyoxalase activities in human tumour cell lines in vitro.
Neoplasms
Glyoxalase activities in tumor and non-tumor human urogenital tissues.
Neoplasms
Glyoxalase I (GLO1) is Up-regulated in Pancreatic Cancerous Tissues Compared with Related Non-cancerous Tissues.
Neoplasms
Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy.
Neoplasms
Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.
Neoplasms
Glyoxalase I in detoxification: studies using a glyoxalase I transfectant cell line.
Neoplasms
Glyoxalase I in tumor cell proliferation and survival and as a potential target for anticancer therapy.
Neoplasms
Glyoxalase I inhibitors in cancer chemotherapy.
Neoplasms
Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.
Neoplasms
Glyoxalase in tumourigenesis and multidrug resistance.
Neoplasms
Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance.
Neoplasms
Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression.
Neoplasms
High expression of GLO1 indicates unfavorable clinical outcomes in glioma patients.
Neoplasms
Identification of immunodominant regions of Brassica juncea glyoxalase I as potential antitumor immunomodulation targets.
Neoplasms
Identification of the first "two digit nano-molar" inhibitors of the human glyoxalase-I enzyme as potential anticancer agents.
Neoplasms
Imaging Tumorous Methylglyoxal by an Activatable Near-Infrared Fluorescent Probe for Monitoring Glyoxalase 1 Activity.
Neoplasms
Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance.
Neoplasms
Inhibition of glyoxalase I by the enediol mimic S-(N-hydroxy-N-methylcarbamoyl)glutathione. The possible basis of a tumor-selective anticancer strategy.
Neoplasms
Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma.
Neoplasms
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Neoplasms
Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells.
Neoplasms
Long-term intake of the reactive metabolite methylglyoxal is not toxic in mice.
Neoplasms
Low red blood cell levels of deglycating enzymes in colorectal cancer patients.
Neoplasms
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Neoplasms
Molecular cancer therapeutics: recent progress and targets in drug resistance.
Neoplasms
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Neoplasms
Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.
Neoplasms
Phytochemicals against anti-diabetic complications: targeting the advanced glycation end product signaling pathway.
Neoplasms
Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I.
Neoplasms
Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.
Neoplasms
Potential of glycative stress targeting for cancer prevention.
Neoplasms
Preventive Effect of Eucalyptol on the Formation of Aorta Lesions in the Diabetic-Atherosclerotic Rat.
Neoplasms
Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.
Neoplasms
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Neoplasms
Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma.
Neoplasms
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer.
Neoplasms
Recent Advances in Glyoxalase-I Inhibition.
Neoplasms
Selenium level and glutathione-dependent enzyme activities in normal and neoplastic human lung tissues.
Neoplasms
Structural basis for 18-?-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor.
Neoplasms
Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects.
Neoplasms
Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway.
Neoplasms
The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice.
Neoplasms
The tumor promoting phorbol diester, 12-O-tetradecanoylphorbol-13-acetate (TPA) increases glyoxalase I and decreases glyoxalase II activity in human polymorphonuclear leukocytes.
Neoplasms
Thermal copoly(amino acids) as inhibitors of glyoxalase I.
Neoplasms
TLSC702, a Novel Inhibitor of Human Glyoxalase I, Induces Apoptosis in Tumor Cells.
Neoplasms
Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes.
Neoplasms
Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE.
Neoplasms
Tumour necrosis factor induces phosphorylation primarily of the nitric-oxide-responsive form of glyoxalase I.
Neoplasms
Up-regulation of the tumor promoter Glyoxalase-1 indicates poor prognosis in breast cancer.
Neoplasms
[Metformin--new treatment strategies for gynecologic neoplasms].
Neuritis
HLA antigens in the Landry-Guillain-Barré syndrome and chronic relapsing polyneuritis.
Neuritis
Pathological effects of glyoxalase I inhibition in SH-SY5Y neuroblastoma cells.
Neuroblastoma
Pathological effects of glyoxalase I inhibition in SH-SY5Y neuroblastoma cells.
Neurodegenerative Diseases
C332C genotype of glyoxalase 1 and its association with late diabetic complications.
Neurodegenerative Diseases
High-fructose intake as risk factor for neurodegeneration: Key role for carboxy methyllysine accumulation in mice hippocampal neurons.
Neurodegenerative Diseases
Role for glyoxalase I in Alzheimer's disease.
Neuroendocrine Tumors
Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET).
Non-alcoholic Fatty Liver Disease
Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Obesity
Dicarbonyl stress in clinical obesity.
Obesity
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Obesity
Glyoxalase 1 Modulation in Obesity and Diabetes.
Obesity
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Obesity
Pharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in Muscle.
Oligodendroglioma
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents.
Osteoarthritis
Impairment of glyoxalase-1, an advanced glycation end-product detoxifying enzyme, induced by inflammation in age-related osteoarthritis.
Ovarian Neoplasms
Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.
Ovarian Neoplasms
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Overweight
Dicarbonyl stress in clinical obesity.
Overweight
Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation.
Overweight
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Overweight
Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation.
Pancreatic Neoplasms
Soluble receptor for advanced glycation end-products (RAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer.
Pancreatitis, Chronic
Common variants in glyoxalase I do not increase chronic pancreatitis risk.
Paracoccidioidomycosis
[The association between glyoxalase I and paracoccidioidomycosis infection]
Parasitemia
Glyoxalase-I activity levels in peripheral blood of Ghanaian Africans with or without Plasmodium falciparum.
Parkinson Disease
HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type.
Polycystic Ovary Syndrome
Reduced Ovarian Glyoxalase-I Activity by Dietary Glycotoxins and Androgen Excess: A Causative Link to Polycystic Ovarian Syndrome.
Pre-Eclampsia
Evidence for increased methylglyoxal in the vasculature of women with preeclampsia: role in upregulation of LOX-1 and arginase.
Prostatic Hyperplasia
Glyoxalase activities in tumor and non-tumor human urogenital tissues.
Prostatic Intraepithelial Neoplasia
Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer.
Prostatic Neoplasms
A possible regulatory role of glyoxalase I in cell viability of human prostate cancer.
Prostatic Neoplasms
Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I.
Prostatic Neoplasms
Exploring glyoxalase 1 expression in prostate cancer tissues: Targeting the enzyme by ethyl pyruvate defangs some malignancy-associated properties.
Prostatic Neoplasms
Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer.
Prostatic Neoplasms
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.
Prostatic Neoplasms
Glyoxalase 1-419C>A Variant Is Associated with Oxidative Stress: Implications in Prostate Cancer Progression.
Prostatic Neoplasms
Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy.
Prostatic Neoplasms
Glyoxalase I phenotype as a potential risk factor for prostate carcinoma.
Prostatic Neoplasms
High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
Prostatic Neoplasms
Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells.
Prostatic Neoplasms, Castration-Resistant
Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I.
Proteinuria
Preventive Effect of Eucalyptol on the Formation of Aorta Lesions in the Diabetic-Atherosclerotic Rat.
Renal Insufficiency
Long-term intake of the reactive metabolite methylglyoxal is not toxic in mice.
Renal Insufficiency, Chronic
Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.
Reperfusion Injury
Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats.
Sarcoma
Further studies on liver glyoxalase I and glyoxalase II. Activity in mice bearing sarcoma 180 and L1210 leukemia.
Sarcoma
Studies on methylglyoxal. II. Changes of methylglyoxal level accompanying the changes of glyoxalase I and II activities in mice bearing L1210 leukemia and sarcoma 180.
Sarcoma
Synthesis and cytotoxicity of shikimate analogues. Structure:activity studies based on 1-crotonyloxymethyl-3R,4R,5R-trihydroxycyclohex-2-enone.
Sarcoma 180
Further studies on liver glyoxalase I and glyoxalase II. Activity in mice bearing sarcoma 180 and L1210 leukemia.
Sarcoma 180
Studies on methylglyoxal. II. Changes of methylglyoxal level accompanying the changes of glyoxalase I and II activities in mice bearing L1210 leukemia and sarcoma 180.
Seizures
Genetic and Pharmacological Manipulations of Glyoxalase 1 Mediate Ethanol Withdrawal Seizure Susceptibility in Mice.
Seizures
Glyoxalase 1 and its substrate methylglyoxal are novel regulators of seizure susceptibility.
Seizures
Inhibition of Glyoxalase 1 reduces alcohol self-administration in dependent and nondependent rats.
Seizures
Role of glyoxalase I gene polymorphisms in late-onset epilepsy and drug-resistant epilepsy.
Sleep Initiation and Maintenance Disorders
Liquid chromatography-mass spectrometry in-depth analysis and in silico verification of the potential active ingredients of Baihe Dihuang decoction in vivo and in vitro.
Spinocerebellar Ataxias
Linkage studies on glyoxalase I (GLO), pepsinogen (PG), spinocerebellar ataxia (SCA1), and HLA.
Squamous Cell Carcinoma of Head and Neck
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
steroid 21-monooxygenase deficiency
Gene frequencies and genetic linkage disequilibrium for the HLA-linked genes Bf, C2, C4S, C4F, 21-hydroxylase deficiency, and glyoxalase I.
Stomach Neoplasms
Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression.
Stomach Neoplasms
Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer.
Subacute Sclerosing Panencephalitis
Partial C4 deficiency in subacute sclerosing panencephalitis.
Thrombocytosis
Platelet glyoxalases in thrombocytosis.
Tyrosinemias
Representing and reasoning about protein families using generative and discriminative methods.
Urinary Bladder Neoplasms
Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.
Urolithiasis
Experimental urolithiasis : Part II--a comparative kinetic study of glyoxalase I, glycolate oxidase, alkaline phosphatase & lactate dehydrogenase in the normal rat kidney & bladder & its alterations in urolithiasis.
Vascular Diseases
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.
Vascular Diseases
Glyoxalase I (Glo1) and its metabolites in vascular disease.
Vascular Malformations
GLYOXALASE I A111E, PARAOXONASE 1 Q192R AND L55M POLYMORPHISMS IN ITALIAN PATIENTS WITH SPORADIC CEREBRAL CAVERNOUS MALFORMATIONS: A PILOT STUDY.
Ventricular Dysfunction
Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic Cardiomyopathy.
Vitamin B 6 Deficiency
Combined glyoxalase 1 dysfunction and vitamin B6 deficiency in a schizophrenia model system causes mitochondrial dysfunction in the prefrontal cortex.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
vander Jagt, D.L.
The glyoxalase system
Coenzymes and cofactors, Glutathione, Chem. Biochem. Med. Aspects Pt. A (Dolphin D, Poulson R, Avromonic O, eds. ) John Wiley & Sons, New York
3
597-641
1989
Saccharomyces cerevisiae, Oryctolagus cuniculus, Escherichia coli, Ovis aries, Homo sapiens, Mus musculus, Rattus norvegicus, Rhodospirillum rubrum, Sus scrofa
-
brenda
Mannervik, B.; Aronsson, A.C.; Tibbelin, G.
Glyoxalase I from human erythrocytes
Methods Enzymol.
90
535-541
1982
Homo sapiens
brenda
Marmstal, E.; Aronsson, A.C.; Mannervik, B.
Comparison of glyoxalase I purified from yeast (Saccharomyces cerevisiae) with the enzyme from mammalian sources
Biochem. J.
183
23-30
1979
Saccharomyces cerevisiae, Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Aronsson, A.C.; Tibbelin, G.; Mannervik, B.
Purification of glyoxalase I from human erythrocytes by the use of affinity chromatography and separation of the three isoenzymes
Anal. Biochem.
92
390-393
1979
Homo sapiens
brenda
Cameron, A.D.; Olin, B.; Ridderstrom, M.; Mannervik, B.; Jones, T.A.
Crystal structure of human glyoxalase I - evidence for gene duplication and 3D domain swapping
EMBO J.
16
3395-3395
1997
Homo sapiens
-
brenda
Ranganathan, S.; Walsh, E.S.; Godwin, A.K.; Tew, K.D.
Cloning and characterization of human colon glyoxalase-I
J. Biol. Chem.
268
5661-5667
1993
Homo sapiens
brenda
Kim, N.S.; Sekine, S.; Kiuchi, N.; Kato, S.
cDNA cloning and characterization of human glyoxalase I isoforms from HT-1080 cells
J. Biochem.
117
359-361
1995
Homo sapiens
brenda
Allen, R.E.; Lo, T.W.C.; Thornalley, P.J.
Inhibitors of glyoxalase I: design, synthesis, inhibitory characteristics and biological evaluation
Biochem. Soc. Trans.
21
535-540
1993
Saccharomyces cerevisiae, Homo sapiens
brenda
Allen, R.E.; Lo, T.W.C.; Thornalley, P.J.
A simplified method for the purification of human red blood cell glyoxalase. I. Characteristics, immunoblotting, and inhibitor studies
J. Protein Chem.
12
111-119
1993
Homo sapiens
brenda
Shinohara, M.; Thornalley, P.J.; Giardino, I.; Beisswenger, P.; Thorpe, S.R.; Onorato, J.; Brownlee, M.
Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis
J. Clin. Invest.
101
1142-1147
1998
Homo sapiens
brenda
Creighton, D.J.; Hamilton, D.S.
Brief history of glyoxalase I and what we have learned about metal ion-dependent, enzyme-catalyzed isomerizations
Arch. Biochem. Biophys.
387
1-10
2001
Saccharomyces cerevisiae, Escherichia coli, Homo sapiens
brenda
Mitsumoto, A.; Kim, K.R.; Oshima, G.; Kunimoto, M.; Okawa, K.; Iwamatsu, A.; Nakagawa, Y.
Glyoxalase I is a novel nitric-oxide-responsive protein
Biochem. J.
344
837-844
1999
Homo sapiens
brenda
Cameron, A.D.; Ridderstrom, M.; Olin, B.; Kavarana, M.J.; Creighton, D.J.; Mannervik, B.
Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue
Biochemistry
38
13480-13490
1999
Homo sapiens (Q04760), Homo sapiens
brenda
Sakamoto, H.; Mashima, T.; Kizaki, A.; Dan, S.; Hashimoto, Y.; Naito, M.; Tsuruo, T.
Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis
Blood
95
3214-3218
2000
Homo sapiens
brenda
Himo, F.; Siegbahn, P.E.
Catalytic mechanism of glyoxalase I: a theoretical study
J. Am. Chem. Soc.
123
10280-10289
2001
Homo sapiens
brenda
ichter, U.; Krauss, M.
Active site structure and mechanism of human glyoxalase I-an ab initio theoretical study
J. Am. Chem. Soc.
123
6973-6982
2001
Homo sapiens
brenda
Lupidi, G.; Bollettini, M.; Venardi, G.; Marmocchi, F.; Rotilio, G.
Functional residues on the enzyme active site of glyoxalase I from bovine brain
Prep. Biochem. Biotechnol.
31
317-329
2001
Bos taurus, Saccharomyces cerevisiae, Homo sapiens
brenda
Davidson, S.D.; Milanesa, D.M.; Mallouh, C.; Choudhury, M.S.; Tazaki, H.; Konno, S.
A possible regulatory role of glyoxalase I in cell viability of human prostate cancer
Urol. Res.
30
116-121
2002
Homo sapiens
brenda
Akoachere, M.; Iozef, R.; Rahlfs, S.; Deponte, M.; Mannervik, B.; Creighton, D.J.; Schirmer, H.; Becker, K.
Characterization of the glyoxalases of the malarial parasite Plasmodium falciparum and comparison with their human counterparts
Biol. Chem.
386
41-52
2005
Homo sapiens, Plasmodium falciparum
brenda
Antognelli, C.; Baldracchini, F.; Talesa, V.N.; Costantini, E.; Zucchi, A.; Mearini, E.
Overexpression of glyoxalase system enzymes in human kidney tumor
Cancer J.
12
222-228
2006
Homo sapiens, Homo sapiens (Q04760)
brenda
Miller, A.G.; Smith, D.G.; Bhat, M.; Nagaraj, R.H.
Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions
J. Biol. Chem.
281
11864-11871
2006
Homo sapiens
brenda
Ariza, A.; Vickers, T.J.; Greig, N.; Armour, K.A.; Dixon, M.J.; Eggleston, I.M.; Fairlamb, A.H.; Bond, C.S.
Specificity of the trypanothione-dependent Leishmania major glyoxalase I: structure and biochemical comparison with the human enzyme
Mol. Microbiol.
59
1239-1248
2006
Homo sapiens (Q04760), Homo sapiens, Leishmania major (Q68RJ8), Leishmania major
brenda
Kuhla, B.; Boeck, K.; Schmidt, A.; Ogunlade, V.; Arendt, T.; Muench, G.; Lueth, H.J.
Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimers disease brains
Neurobiol. Aging
28
29-41
2007
Homo sapiens
brenda
Korybalska, K.; Wisniewska-Elnur, J.; Trominska, J.; Joerres, A.; Breborowicz, A.; Witowski, J.
The role of the glyoxalase pathway in reducing mesothelial toxicity of glucose degradation products
Perit. Dial. Int.
26
259-265
2006
Homo sapiens
brenda
Ahmed, U.; Dobler, D.; Larkin, S.J.; Rabbani, N.; Thornalley, P.J.
Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro
Ann. N. Y. Acad. Sci.
1126
262-264
2008
Homo sapiens
brenda
Kalousova, M.; Germanova, A.; Jachymova, M.; Mestek, O.; Tesar, V.; Zima, T.
A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients
Ann. N. Y. Acad. Sci.
1126
268-271
2008
Homo sapiens
brenda
Takasawa, R.; Takahashi, S.; Saeki, K.; Sunaga, S.; Yoshimori, A.; Tanuma, S.
Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects
Bioorg. Med. Chem.
16
3969-3975
2008
Homo sapiens (Q04760), Homo sapiens
brenda
Sukdeo, N.; Honek, J.F.
Microbial glyoxalase enzymes: metalloenzymes controlling cellular levels of methylglyoxal
Drug Metabol. Drug Interact.
23
29-50
2008
Escherichia coli, Escherichia coli (P0AC81), Homo sapiens, Homo sapiens (Q04760), Leishmania braziliensis, Leishmania donovani, Leishmania major, Leishmania sp., Neisseria meningitidis, Neisseria meningitidis (P0A0T3), Plasmodium falciparum, Pseudomonas aeruginosa, Pseudomonas aeruginosa (Q9HU72), Pseudomonas aeruginosa (Q9HY85), Pseudomonas aeruginosa (Q9I5L8), Pseudomonas putida, Pseudomonas putida (Q88GF8), Trypanosoma cruzi, Yersinia pestis
brenda
de Hemptinne, V.; Rondas, D.; Toepoel, M.; Vancompernolle, K.
Phosphorylation on Thr-106 and NO-modification of glyoxalase I suppress the TNF-induced transcriptional activity of NF-kappaB
Mol. Cell. Biochem.
325
169-178
2009
Homo sapiens
brenda
Santel, T.; Pflug, G.; Hemdan, N.Y.; Schaefer, A.; Hollenbach, M.; Buchold, M.; Hintersdorf, A.; Lindner, I.; Otto, A.; Bigl, M.; Oerlecke, I.; Hutschenreuter, A.; Sack, U.; Huse, K.; Groth, M.; Birkemeyer, C.; Schellenberger, W.; Gebhardt, R.; Platzer, M.; Weiss, T.; Vijayalakshmi, M.A.; Krueger, M.
Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity
PLoS ONE
3
e3508
2008
Homo sapiens
brenda
Inagi, R.; Kumagai, T.; Fujita, T.; Nangaku, M.
The role of glyoxalase system in renal hypoxia
Adv. Exp. Med. Biol.
662
49-55
2010
Homo sapiens
brenda
Mailankot, M.; Padmanabha, S.; Pasupuleti, N.; Major, D.; Howell, S.; Nagaraj, R.H.
Glyoxalase I activity and immunoreactivity in the aging human lens
Biogerontology
10
711-720
2009
Homo sapiens
brenda
Liu, M.; Yuan, M.; Luo, M.; Bu, X.; Luo, H.B.; Hu, X.
Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis
Biophys. Chem.
147
28-34
2010
Homo sapiens (Q04760)
brenda
Louie, B.; Rajamahanty, S.; Pyo, P.; Choudhury, M.; Konno, S.
Mode of cytotoxic action of nephrotoxic agents: oxidative stress and glutathione-dependent enzyme
BJU Int.
105
264-268
2010
Homo sapiens
brenda
Antognelli, C.; Del Buono, C.; Ludovini, V.; Gori, S.; Talesa, V.N.; Crino, L.; Barberini, F.; Rulli, A.
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study
BMC Cancer
9
115
2009
Homo sapiens
brenda
Germanova, A.; Germanova, A.; Tesarova, P.; Jachymova, M.; Zvara, K.; Zima, T.; Kalousova, M.
Glyoxalase I Glu111Ala polymorphism in patients with breast cancer
Cancer Invest.
27
655-660
2009
Homo sapiens
brenda
Takeuchi, M.; Kimura, S.; Kuroda, J.; Ashihara, E.; Kawatani, M.; Osada, H.; Umezawa, K.; Yasui, E.; Imoto, M.; Tsuruo, T.; Yokota, A.; Tanaka, R.; Nagao, R.; Nakahata, T.; Fujiyama, Y.; Maekawa, T.
Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment
Cell Death Differ.
17
1211-1220
2010
Homo sapiens
brenda
Davies, G.F.; Juurlink, B.H.; Harkness, T.A.
Troglitazone reverses the multiple drug resistance phenotype in cancer cells
Drug Des. Devel. Ther.
3
79-88
2009
Homo sapiens
brenda
Engelen, L.; Ferreira, I.; Brouwers, O.; Henry, R.M.; Dekker, J.M.; Nijpels, G.; Heine, R.J.; van Greevenbroek, M.M.; van der Kallen, C.J.; Blaak, E.E.; Feskens, E.J.; ten Cate, H.; Stehouwer, C.D.; Schalkwijk, C.G.
Polymorphisms in glyoxalase 1 gene are not associated with vascular complications: the Hoorn and CoDAM studies
J. Hypertens.
27
1399-1403
2009
Homo sapiens
brenda
More, S.S.; Vince, R.
Inhibition of glyoxalase I: the first low-nanomolar tight-binding inhibitors
J. Med. Chem.
52
4650-4656
2009
Homo sapiens
brenda
Helgager, J.; Li, J.; Lubensky, I.A.; Lonser, R.; Zhuang, Z.
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents
J. Oncol.
2010
373491
2010
Homo sapiens
brenda
Bair, W.B.; Cabello, C.M.; Uchida, K.; Bause, A.S.; Wondrak, G.T.
GLO1 overexpression in human malignant melanoma
Melanoma Res.
20
85-96
2010
Homo sapiens
brenda
Karg, E.; Papp, F.; Tassi, N.; Janaky, T.; Wittmann, G.; Turi, S.
Enhanced methylglyoxal formation in the erythrocytes of hemodialyzed patients
Metab. Clin. Exp.
58
976-982
2009
Homo sapiens
brenda
Thornalley, P.J.; Waris, S.; Fleming, T.; Santarius, T.; Larkin, S.J.; Winklhofer-Roob, B.M.; Stratton, M.R.; Rabbani, N.
Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance
Nucleic Acids Res.
38
5432-5442
2010
Homo sapiens
brenda
Birkenmeier, G.; Stegemann, C.; Hoffmann, R.; Guenther, R.; Huse, K.; Birkemeyer, C.
Posttranslational modification of human glyoxalase 1 indicates redox-dependent regulation
PLoS ONE
5
e10399
2010
Homo sapiens (Q04760), Homo sapiens
brenda
Thornalley, P.J.; Rabbani, N.
Highlights and hotspots of protein glycation in end-stage renal disease
Semin. Dial.
22
400-404
2009
Homo sapiens
brenda
Liu, M.; Yuan, M.; Li, Z.; Cheng, Y.K.; Luo, H.B.; Hu, X.
Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I
Bioorg. Med. Chem. Lett.
21
4243-4247
2011
Homo sapiens
brenda
Takasawa, R.; Tao, A.; Saeki, K.; Shionozaki, N.; Tanaka, R.; Uchiro, H.; Takahashi, S.; Yoshimori, A.; Tanuma, S.
Discovery of a new type inhibitor of human glyoxalase I by myricetin-based 4-point pharmacophore
Bioorg. Med. Chem. Lett.
21
4337-4342
2011
Homo sapiens
brenda
Yuan, M.; Luo, M.; Song, Y.; Xu, Q.; Wang, X.; Cao, Y.; Bu, X.; Ren, Y.; Hu, X.
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies
Bioorg. Med. Chem.
19
1189-1196
2011
Homo sapiens
brenda
Skapare, E.; Riekstina, U.; Liepinsh, E.; Konrade, I.; Makrecka, M.; Maurina, B.; Dambrova, M.
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes
Cell Biochem. Funct.
29
171-174
2011
Homo sapiens
brenda
Hanssen, N.M.; Stehouwer, C.D.; Schalkwijk, C.G.
Methylglyoxal and glyoxalase I in atherosclerosis
Biochem. Soc. Trans.
42
443-449
2014
Homo sapiens
brenda
Deponte, M.
Glyoxalase diversity in parasitic protists
Biochem. Soc. Trans.
42
473-478
2014
Homo sapiens, Leishmania braziliensis, Leishmania donovani, Leishmania infantum, Leishmania major, no activity in Entamoeba histolytica, Plasmodium falciparum, Trypanosoma cruzi, no activity in Trypanosoma brucei, no activity in Giardia lamblia
brenda
Honek, J.F.
Bacterial glyoxalase I enzymes: structural and biochemical investigations
Biochem. Soc. Trans.
42
479-484
2014
Saccharomyces cerevisiae, Clostridium acetobutylicum, Escherichia coli, Homo sapiens, Leishmania donovani, Leishmania infantum, Leishmania major, Neisseria meningitidis, Yersinia pestis, Plasmodium falciparum, Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas syringae, Trypanosoma cruzi
brenda
Wortmann, M.; Peters, A.S.; Hakimi, M.; Boeckler, D.; Dihlmann, S.
Glyoxalase I (Glo1) and its metabolites in vascular disease
Biochem. Soc. Trans.
42
528-533
2014
Homo sapiens, Mus musculus
brenda
Chiba, T.; Ohwada, J.; Sakamoto, H.; Kobayashi, T.; Fukami, T.A.; Irie, M.; Miura, T.; Ohara, K.; Koyano, H.
Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors
Bioorg. Med. Chem. Lett.
22
7486-7489
2012
Homo sapiens
brenda
Holewinski, R.J.; Creighton, D.J.
Inhibition by active site directed covalent modification of human glyoxalase I
Bioorg. Med. Chem.
22
3301-3308
2014
Homo sapiens
brenda
Hikita, K.; Yamada, S.; Shibata, R.; Katoh, M.; Murata, T.; Kato, K.; Tanaka, H.; Kaneda, N.
Inhibitory effect of isoflavones from Erythrina poeppigiana on the growth of HL-60 human leukemia cells through inhibition of glyoxalase I
Nat. Prod. Commun.
10
1581-1584
2015
Homo sapiens (Q04760), Homo sapiens
brenda